References
- Garcia-Manero G, Faderl S, O’Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 2003;98: 437–57.
- Marshall HM, Hammond JM. Treatment options in imatinib-resistant chronic myelogenous leukemia. Ann Pharmacother 2008;42:259–64.
- Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615–9.
- Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, . Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–16.
- Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011–9.
- Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–44.
- Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48: 964–70.
- Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, . Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542–51.
- Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, . Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–6.
- le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, . Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834–9.
- Edling CE, Hallberg B. c-Kit–a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007;39: 1995–8.
- Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, . ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531–40.
- Madsen JK, Hommel E, Hansen JF. Prognostic value of an electrocardiogram at rest and exercise test in patients admitted with suspected acute myocardial infarction, in whom the diagnosis is not confirmed. Eur Heart J 1987; 8:717–24.
- Fruergaard P, Launbjerg J, Jacobsen HL, Madsen JK. Seven-year prognostic value of the electrocardiogram at rest and an exercise test in patients admitted for, but without, confirmed myocardial infarction. Eur Heart J 1993;14:499–504.
- Madsen JK, Thomsen BL, Mellemgaard K, Hansen JF. Independent prognostic risk factors for patients referred because of suspected acute myocardial infarction without confirmed diagnosis. Prognosis after discharge in relation to medical history and non-invasive investigations. Eur Heart J 1988; 9:610–8.
- Muscholl MW, Oswald M, Mayer C, von Scheidt W. Prognostic value of 2D echocardiography in patients presenting with acute chest pain and non-diagnostic ECG for ST-elevation myocardial infarction. Int J Cardiol 2002;84:217–25.